Shanghai Medicilon Inc.

Concepts and types of biopharmaceuticals Biological drugs (biopharmaceutics or biopharmaceuticals) are natural biologically active substances and artificially synthesized or semi-synthesized natural substances that are prepared from components such as organisms, biological tissues, or organs, and comprehensively apply the principles and methods of biology, biochemistry, and other disciplines. Biological drugs mainly include biochemical drugs, biotechnology drugs, and biological products. Biochemical drugs: generally refer to the basic substances of life extracted from animals, plants and microorganisms, which can also be semi-synthesized by bio-chemistry, or obtained by modern biotechnology, such as amino acids, polypeptides, proteins, enzymes, coenzymes, polysaccharides , nucleotides, lipids and biogenic amines, as well as their derivatives, degradation products and structural modifications of macromolecules. Biotechnology drugs: refer to drugs derived from biological sources and manu

  On June 12, 2023, MindRank, which focuses on the use of AI to drive the development of new drugs, announced that the phase I clinical trial of its self-developed GLP-1RA small molecule oral drug MDR-001 successfully completed the first subject administration.  MDR-001 is for the treatment of indications such as obesity and type 2 diabetes. Shanghai Medicilon Inc. (Medicilon), as a strategic partner of MindRank, provided MDR-001 with  API process development and preparation R&D services  to help speed up its research and development. Medicilon GLP-1 New Drug R&D Services  One-stop support for new drug development and innovation From "powerful" hypoglycemic drugs to "miracle" weight-loss drugs, the huge market space of GLP-1 is attracting more attention.  As a one-stop biopharmaceutical preclinical research and development service platform, Medicilon has already established a presence in the GLP-1 field, and can provide clients with GLP-1 drug discovery, GLP

  On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released and grandly awarded at the "2023 Conference on High Quality Development of Healthcare Industry & the Eight Summit for China Pharmaceutical R&D Innovation"!  Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List. This is also the 4th consecutive year that Medicilon has won this honor! The selection of "Top 20 Chinese R&D CRO Enterprises in 2023" list is strictly based on the 10 indicators such as company's annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, number of employees, number of employees growth, brand popularity and leader in subdivided fields.  The list represents the highest level of  China's pharmaceutical CRO/CDMO industry .

Recently, the IND application of TollB-001 Tablets, a class 1.1 new drug for rheumatoid arthritis by Toll Biotech, has been officially approved by the FDA, allowing clinical trials to be carried out in the United States.  This is another milestone after TollB-001 tablet of Toll Biotech was accepted by China CDE.  It is also an important step in Toll Biotech's international commercialization and expansion of overseas markets. Shanghai Medicilon Inc. (Medicilon), as a partner of Toll Biotech, provided  pharmaceutical research services , including raw materials and preparation, for TollB-001 tablets, which accelerated the research process. Class 1.1 new drug TollB-001 tablet  Drugs for Autoimmune Diseases with a New Mechanism TollB-001 tablet is a class 1.1 small molecule new drug developed for rheumatoid arthritis launched by Toll Biotech.  Preclinical studies have shown that its efficacy and safety are significantly superior to clinical first-line drugs.  It is a class 1 of oral new

  Recently, Shanghai Medicilon Inc. (Medicilon) and DP Technology Ltd. announced the signing of a strategic collaboration agreement.  The two parties will work together to build an integrated AI platform for early drug discovery and evaluation based on AI4S. Medicilon: Build an AI-based one-stop preclinical R&D service platform At present, the AI+CRO model is rapidly gaining popularity around the world and is accelerating the transformation of the biopharmaceutical industry.  As a supporter of emerging technologies, Medicilon has been actively exploring the frontier technologies of drug development for 19 years.  In the field of AI pharmaceuticals, on the basis of collaboration with a number of AI innovative drug R&D companies, Medicilon will use the druggability evaluation and prediction platform of virtual drugs, drug intelligent target database, drug-molecule database, drug binding model database, drug designed AI generation model and AI virtual drug screening system and oth

  On June 12, 2023, the list of "18th China Listed Companies Competitive Credibility Company" organized by Chinese Securities Journal was announced.   Shanghai Medicilon Inc . (Medicilon) was awarded the "2023 Growth Potential Company" by virtue of its stable and excellent profitability, innovation ability, and competitive strength.

  On the one hand, the burden on the eyes brought by electronic products has increased, and on the other hand, the eye health awareness of "seeing clearly and comfortably" has been improved.  High Growth, High Barriers, and High Prosperity Chinese ophthalmic drugs are rising explosively! The number of ophthalmology patients in China far exceeds that of the United States, reaching 1 billion, but the ophthalmic drug market is less than one-fifth of that of the United States.  In China's ophthalmic drug market, which started relatively late, the understanding of the pathogenesis of ophthalmic diseases is relatively lagging behind, and the innovative R&D capabilities are relatively weak.  It can be said that independent research and development of ophthalmic drugs is destined to be a road of groping in the dark.  On this road, Raymon Pharma is constantly moving forward with the lights on, exploring the dream of light. In March 2023, the eye drops RA1115-B1 self-developed

  Recently, Raymon Pharma announced that the clinical trial of self-developed RA1115-B1 eye drops for the treatment of neovascular (wet) age-related macular degeneration (wAMD) was launched in China.  The Phase I clinical trial at Peking Union Medical College Hospital of the Academy of Medical Sciences, chaired by the principal investigators Professor Youxin Chen and Associate Professor Rui Che, has been completed with positive results. In the research and development of RA1115-B1 eye drops, Shanghai Medicilon Inc. (Medicilon) provided pharmaceutical research services such as raw material drug production, raw material drug process development, and preparation prescription process development to accelerate the R&D process. The first eye drops for the treatment of wAMD in China The therapeutic potential of RA1115-B1 is initially shown Wet age-related macular degeneration is a vision killer for middle-aged and elderly people.  Among the irreversible blinding eye diseases in the world

Type 2 diabetes is a progressive disease. The disease course is primarily characterized by a decline in β-cell function and worsening of insulin resistance. Therefore, various antidiabetic agents are under research and development. The hypoglycemic strategy has also shifted from "sugar control" to both "sugar control" and "heart protection". GLP-1R agonists can improve left ventricular ejection fraction, myocardial contractility, coronary blood flow, cardiac output, and endothelial function while reducing infarction size and overall risks for a cardiovascular event. Other functions of GLP-1 include increased glucose uptake in the muscles, decreased glucose production in the liver, neuroprotection, and increased satiety due to direct actions on the hypothalamus. At present, the therapeutic application and potential value of GLP-1RAs in diabetes has become a research hotspot. In the formulation of GLP-1 integrated research plan, Medicilon has in-depth commun